Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile - Archive ouverte HAL Access content directly
Journal Articles Antimicrobial Agents and Chemotherapy Year : 2021

Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile

Abstract

Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Dates and versions

hal-03633663 , version 1 (07-04-2022)

Identifiers

Cite

Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, et al.. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy, 2021, 65 (9), pp.e0104321. ⟨10.1128/AAC.01043-21⟩. ⟨hal-03633663⟩
49 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More